Santhera Pharmaceuticals Holding AG

SWX:SANN Stock Report

Market Cap: CHF 126.6m

Santhera Pharmaceuticals Holding Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SANN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders55,8170.461%
Private Companies280,1372.31%
Institutions1,220,89310.1%
Public Companies2,715,81622.4%
General Public7,833,43064.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.5%.

Top Shareholders

Top 20 shareholders own 35.29% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.7%
Catalyst Pharmaceuticals, Inc.
1,414,688CHF 14.8m0%no data
10.8%
Idorsia Ltd
1,301,128CHF 13.6m0%no data
8.52%
JPMorgan Chase & Co, Brokerage and Securities Investments
1,031,673CHF 10.8m6,300%0.01%
2.31%
Santhera Pharmaceuticals (Schweiz) AG
280,137CHF 2.9m-86%no data
0.55%
ZKB Asset Management
66,625CHF 696.9k2.22%no data
0.39%
Zürcher Kantonalbank, Investment Arm
47,239CHF 494.1k0%no data
0.26%
Thomas Meier
31,083CHF 325.1k0%no data
0.21%
Pictet Asset Management SA
25,042CHF 261.9k0%no data
0.17%
BlackRock, Inc.
20,605CHF 215.5k1.55%no data
0.15%
Dimensional Fund Advisors LP
18,570CHF 194.2k102%no data
0.11%
Philipp Gutzwiller
13,497CHF 141.2k0%no data
0.064%
Lombard Odier Asset Management (Switzerland) SA
7,695CHF 80.5k0%no data
0.037%
Dario Eklund
4,500CHF 47.1k0%no data
0.026%
Bradley Meyer
3,091CHF 32.3k0%no data
0.025%
CATAM Asset Management AG
3,000CHF 31.4k0%0.03%
0.022%
Shabir Hasham
2,646CHF 27.7k0%no data
0.0083%
Günther Metz
1,000CHF 10.5k0%no data
0.0019%
Quorus Vermögensverwaltung AG
230CHF 2.4k0%no data
0.0011%
Deka Investment GmbH
130CHF 1.4k0%no data
0.00069%
Migrosbank Asset Management
84CHF 873.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Santhera Pharmaceuticals Holding AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurizio BernasconiBank am Bellevue
Silvia SchanzBank Vontobel AG
Barbora BlahaCredit Suisse